← 返回

免疫治疗在卵巢癌中的作用:进展、挑战与未来展望

英文原题:Role of Immunotherapy in Ovarian Cancer: Advances, Challenges, and Future Perspectives.

查看英文原题

Role of Immunotherapy in Ovarian Cancer: Advances, Challenges, and Future Perspectives.

PubMed 2025/01/01(内容时间) Cancer Treat Res

分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。

中文摘要

卵巢癌(OC)因其诊断时多为晚期、复发率高且生存结局有限,仍然是妇科恶性肿瘤中最具挑战性的疾病之一。免疫治疗已成为癌症治疗中一种变革性的方法,利用免疫系统靶向肿瘤细胞。本章全面概述了OC中的免疫治疗,讨论其机制、关键策略和临床进展。关键领域包括免疫检查点抑制剂(ICIs)、过继细胞疗法(ACT)、癌症疫苗和溶瘤病毒的作用。尽管临床前和临床结果令人鼓舞,但仍存在重大挑战,包括低免疫原性、耐药机制和免疫相关不良事件。讨论了应对这些障碍的策略,如联合治疗、生物标志物指导的方法以及整合人工智能(AI)以实现个体化。探索了新兴方向,包括下一代免疫检查点靶点以及表观遗传和代谢重编程方面的创新,以展望OC免疫治疗的未来。通过应对这些挑战并利用创新策略,免疫治疗有潜力重新定义治疗格局,改善OC患者的生存和生活质量。

展开英文摘要原文

Ovarian cancer (OC) remains one of the most challenging gynecologic malignancies due to its late-stage diagnosis, high recurrence rates, and limited survival outcomes. Immunotherapy has emerged as a transformative approach in cancer treatment, leveraging the immune system to target tumor cells. This chapter provides a comprehensive overview of immunotherapy in OC, discussing its mechanisms, key strategies, and clinical advancements. Key areas include the role of immune checkpoint inhibitors (ICIs), adoptive cell therapies (ACT), cancer vaccines, and oncolytic viruses. Despite promising preclinical and clinical outcomes, significant challenges persist, including low immunogenicity, resistance mechanisms, and immune-related adverse events.

Strategies to address these barriers, such as combination therapies, biomarker-guided approaches, and the integration of artificial intelligence (AI) for personalization, are discussed. Emerging directions, including next-generation immune checkpoint targets and innovations in epigenetic and metabolic reprogramming, are explored to envision the future of immunotherapy in OC.

By addressing these challenges and leveraging innovative strategies, immunotherapy has the potential to redefine the therapeutic landscape, improving survival and quality of life for patients with OC.

论文信息

作者
Garg P、Singhal G、Pareek S、Khan A、Tan T、Wheeler D、Singhal SS
第一作者单位
Department of Chemistry, GLA University, Mathura, Uttar Pradesh, India.India
通讯作者单位
Department of Medical Oncology & Therapeutics Research, Beckman Research Institute, City of Hope, Comprehensive Cancer Center and National Medical Center, Duarte, CA, USA. ssinghal@coh.org.United States
文献类型
综述
期刊
Cancer treatment and research2025
原文标识
PubMed 40847235 · DOI 10.1007/978-3-031-97242-3_10